Cytokines and systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 59, Issue 4, 2000, Pages 243-251

  Dean, Gillian S ^a   Tyrrell Price, Jonathan ^a   Crawley, Esther ^a   Isenberg, David A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; AUTOANTIBODY; C REACTIVE PROTEIN; CYTOKINE; DNA ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 16; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY PRODUCTION; B LYMPHOCYTE; CYTOKINE PRODUCTION; HELPER CELL; HUMAN; KIDNEY DISEASE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034109309     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.59.4.243     Document Type: Review

References (78)

1. 1 Morrow WJW, Nelson L, Watts R, Isenberg DA. Autoimmune rheumatic disease. 2nd ed. Oxford: Oxford University Press, 1999.
2. 2 Jara LJ, Irigoyen L, Ortiz MJ, Zazueta B, Bravo G, Espinoza LR. Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus. Clin Rheumatol 1998;17:110-14.
3. 3 Cherwinski HM, Schumacher JH, Brown KD, Mosmann TR. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J Exp Med 1987;166:1229-44.
4. 4 Mosmann TR, Coffman RL. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989;46:111-47.
5. 5 Cobbold S., Waldmann H. Infectious tolerance. Curr Opin Immunol 1998;10:518-24.
6. 6 Madaio MP, Hodder S, Schwartz RS, Stollar BD. Responsiveness of autoimmune and normal mice to nucleic acid antigens. J Immunol 1984;132:872-6.
7. 7 Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: a major immunogen for pathogenic autoantibody- inducing T cells of lupus. J Exp Med 1993;177:1367-81.
8. 8 Lee SH, Park SH, Min JK, Kim SI, You WH, Hong YS, et al. Decreased tumour necrosis factor-beta production in TNFB*2 homozygote: an important predisposing factor of lupus nephritis in Koreans. Lupus 1997;6:603-9.
9. 9 Lacki JK, Leszczynski P, Kelemen J, Muller W, Mackiewicz SH. Cytokine concentration in serum of lupus erythematosus patients: the effect on acute phase response. J Med 1997;28:99-107.
10. 10 Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC. Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 1999;18:17-22.
11. 11 Emilie D, Llorente L, Galanaud P. Cytokines and lupus. Ann Med Interne (Paris) 1996;147:480-4.
12. 12 Spronk PE, Horst G, Vab Der Gun BT, Limburg PC, Kallenberg CG. Anti-dsDNA production coincides with concurrent B and T cell activation during development of active disease in systemic lupus erythematosus (SLE). Clin Exp Immunol 1996;104:446-53.
13. 13 Spronk PE, Van Der Gun BT, Limburg PC, Kallenberg CG. B cell activation in clinically quiescent systemic lupus erythematosus (SLE) is related to immunoglobulin levels, but not to levels of anti- dsDNA, nor to concurrent T cell activation. Clin Exp Immunol 1993;93:39-44.
14. 14 Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 1990;87:1233-7.
15. 15 Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195-9.
16. 16 Wilson AG, di Giovine FS, Blakemore AI, Duff GW. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet. 1992;1:353-3.
17. 17 D'Alfonso S, Richiardi PM. A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics 1994;39:150-4.
18. 18 Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993;177:557-60.
19. 19 Abraham LJ, French MA, Dawkins RL. Polymorphic MHC ancestral haplotypes affect the activity of tumour necrosis factor-alpha. Clin Exp Immunol 1993;92:14-18.
20. 20 Chen CY, Yen JH, Tsai WC, Wu CS, Chiang W, Tsai JJ, et al The TNF2 allele does not contribute towards susceptibility to systemic lupus erythematosus. Immunol Lett 1997;55:1-3.
21. 21 Hajeer AH, Worthington J, Davies EJ, Hillarby MC, Poulton K, Ollier WE. TNF microsatellite a2, b3 and d2 alleles are associated with systemic lupus erythematosus. Tissue Antigens 1997;49:222-7.
22. 22 Sturfelt G, Hellmer G, Truedsson L. TNF microsatellites in systemic lupus erythematosus-a high frequency of the TNFabc 2-3-1 haplotype in multicase SLE families. Lupus 1996;5:618-22.
23. 23 Gabay C, Cakir N, Moral F, Roux-Lombard P, Meyer O, Dayer JM, et al. Circulating levels of tumour necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997;24:303-8.
24. 24 Symmons DP. Frequency of lupus in people of African origin. Lupus 1995;4:176-8.
25. 25 Tesar V, Jirsa M Jr, Masek Z, Bartunkova J, Stejskalova A, Dostal C, et al. Soluble cytokinin receptors in renal vasculitis and lupus nephritis. Cas Lek Cesk 1998;137:271-5.
26. 26 Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtando R, Avalos-Diaz E. Renal expression of IL-6 and TNF alpha genes in lupus nephritis. Lupus 1998;7:154-8.
27. 27 Brennan DC, Yui MA, Wuthrich RP, Kelley VE. Tumour necrosis factor and IL-1 in New Zealand black/white mice. Enhanced gene expression and acceleration of renal injury. J Immunol 1989;143:3470-5.
28. 28 Kitamura M, Suto T, Yokoo T, Shimizu F, Fine LG. Transforming growth factor-beta 1 is the predominant paracrine inhibitor of macrophage cytokine synthesis produced by glomerular mesangial cells. J Immunol 1996;156:2964-71.
29. 29 Horwitz DA, Gray JD, Ohtsuka K, Hirokawa M, Takahashi T. The immunoregulatory effects of NK cells: the role of TGF-beta and implications for autoimmunity. Immunol Today 1997;18:538-42.
30. 30 Ohtsuka K, Gray JD, Stimmler MM, Horwitz DA. The relationship between defects in lymphocyte production of transforming growth factor-beta1 in systemic lupus erythematosus and disease activity or severity [see comments]. Lupus. 1999;8:90-4.
31. 31 Viallard JF, Pellegrin JL, Ranchin V, Schaeverbeke T, Dehais J, Longy-Boursier M, et al. Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1999;115:189-95.
32. 32 Sturfelt G, Roux-Lombard P, Wollheim FA, Dayer JM. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br J Rheumatol 1997;36:1283-89.
33. 33 Braude IA, Hochberg MC, Arnett FC, Waldmann TA. In vitro suppression of anti-DNA antibody and immunoglobulin synthesis in systemic lupus erythematosus patients by human gamma interferon. J Rheumatol 1988;15:438-44.
34. 34 Funauchi M, Sugishima H, Minoda M, Horiuchi A. Effect of Interferon-gamma on B lymphocytes of patients with systemic lupus erythematosus. J Rheumatol 1991;18:368-72.
35. 35 Mitamura K, Kang H, Tomita Y, Hashimoto H, Sawada S, Horie T. Impaired tumour necrosis factor-alpha (TNF-alpha) production and abnormal B cell response to TNF-alpha in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1991;85:386-91.
36. 36 Elenitsas R, Abell E, Lee YY, Huang J, Deng JS. Comparison of IgG subclass autoantibodies in patients with systemic lupus erythematosus and subacute cutaneous lupus erythematosus. J Dermatol Sci 1990;1:207-15.
37. 37 Haas N, Ryffel B, Le Hir M. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB × NZW)F1 mice. J Immunol 1998;160:3713-8.
38. 38 Barcellini W, Rizzardi GP, Borghi MO, Nicoletti F, Fain C, Del Papa N, et al. In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: lack of relationship with clinical disease activity. Lupus 1996;5:139-45.
39. 39 Huang YP, Perrin LH, Miescher PA, Zubler RH. Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus. J Immunol 1988;141: 827-33.
40. 40 Linker-Israeli M, Quismorio FP Jr Wong DK, Friou GJ. Serum antibodies to human fetal antigens in patients with systemic lupus erythematosus (SLE). J Immunol 1980; 124:1154-9.
41. 41 Horii Y, Iwano M, Hirata E, Shiiki H, Fujii Y, Dohi K, et al. Role of interleukin-6 in the progression of mesiangial proliferative glomerulonephritis. Kidney Int Suppl 1993;39: S71-5
42. 42 Kawano MM, Mihara K, Huang N, Tsujimoto T, Kuramoto A. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin-6 for escaping from apoptosis. Blood 1995;85:487-94.
43. 43 Nagafuchi H, Suzuki N, Mizushima Y, Sakane T. Constitutive expression of IL-6 receptors and their role inthe excessive B cell function in patients with systemic lupus erythematosus. J Immunol 1993;151:6525-34.
44. 44 Kiberd BA. Interleukin-6 receptor blockage ameliorates murine lupus nephritis. J Am Soc Nephrol 1993;4:58-61.
45. 45 Pelton BK, Hylton W, Denman AM. Activation of IL-6 production by UV irradiation of blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 1992;89:251-4.
46. 46 Casciola-Rosen L, Rosen A. Ultraviolet light-induced keratinocyte apoptosis: a potential mechanism for the induction of skin lesions and autoantibody production in LE. Lupus 1997;6:175-80.
47. 47 Hefeneider SH, Cornell KA, Brown LE, Bakke AC, McCoy SL, Bennett RM. Nucleosomes and DNA bind to specific cell-surface molecules on murine cells and induce cytokine production. Clin Immunol Immunopathol 1992;63:245-51.
48. 48 Yoshio T, Masuyama JI, Kohda N, Hirata D, Sato H, Iwamoto M, et al. Association of interleukin 6 release from endothelial cells and pulmonary hypertension in SLE. J Rheumatol 1997;24:489-95.
49. 49 Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997;349:170-3. [Published erratum Lancet 1997;349: 656].
50. 50 Llorente L, Richaud-Patin Y, Couderc J, Alarcon-Segovia D, Ruiz-Soto R, Alcocer-Castillejos N, et al. Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum 1997;40: 1429-35.
51. 51 Bienvenu J, Doche C, Gutowski MC, Lenoble M, Lepape A, Perdrix JP. Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. J Cardiovasc Pharmacol 1995;25 (suppl 2):S80-4.
52. 52 Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1-8.
53. 53 Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL10 gene and further characterization of the 5' flanking sequence. Immunogenetics 1997;46:120-8.
54. 54 Eskdale J, Wordsworth P, Bowman S, Field M, Gallagher G. Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus. Tissue Antigens 1997;49:635-9.
55. 55 Mehrian R, Quismorio FP Jr, Strassman G, Stimmler MM, Horwitz DA, Kitridou RC, et al. Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 1998;41: 596-602.
56. 56 Lazarus M, Hajeer AH, Turner D, Sinnott P, Worthington J, Ollier WE, et al. Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol 1997;24:2314-17.
57. 57 Kube D, Platzer C, von Knethen A, Straub H, Bohlen H, Hafner M, et al. Isolation of the human interleukin 10 promoter. Characterization of the promoter activity in Burkitt's lymphoma cell lines. Cytokine 1995;7:1-7.
58. 58 Mok CC, Lanchbury JS, Chan DW, Lau CS. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41:1090-5.
59. 59 Crawley E, Isenberg DA, Woo P. Polymorphic haplotypes of the IL-10 5' flanking region are not associated with renal disease or serology in Caucasian patients with systemic lupus erythematosus. Arthritis Rheum 1999;42:2017-18.
60. 60 Horwitz DA, Gray JD, Behrendsen SC, Kubin M, Rengaraju M, Ohtsuka K, et al. Decreased production of enterleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum 1998;41:838-44.
61. 61 al-Janadi M, al-Dalaan A, al-Balla S, al-Humaidi M, Raziuddin S. Interleukin-10 (IL-10) secretion in systemic lupus erythematosus and rheumatoid arthritis: IL-10-dependent CD4+CD45RO+ T cell-B cell antibody synthesis. J Clin Immunol 1996;16:198-207.
62. 62 Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, Renauld JC. Serum interleukin 10 titres in systemic lupus erythematosus reflect disease activity. Lupus 1995;4:393-5.
63. 63 Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998;16:283-8.
64. 64 Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181:839-44.
65. 65 de-Waal-Malefyt R, Yssel H, Roncarolo MG, Spits H, de-Vries JE. Interleukin-10. Curr Opin Immunol 1992;4: 314-20.
66. 66 Desai-Mehta A, Lu L, Ramsey-Golden R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996;97:2063-2073.
67. 67 Grammer AC, Bergman MC, Miura Y, Fujita K, Davis LS, Lipsky PE. The CD40 ligand expressed by human B cells costimulates B cell responses. J Immunol 1995;154:4996-5010.
68. 68 Horwitz DA, Jacob CO. The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications. Springer Semin Immunopathol 1994;16:181-200.
69. 69 Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994;152:3685-92.
70. 70 Georgescu L, Vakkalanka RK, Elkon KB, Crow MK. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by fas ligand. J Clin Invest 1997;100:2622-33.
71. 71 Liu TF, Jones BM. Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes. Cytokine 1998;10:140-7.
72. 72 Lee S, Kaneko H, Sekigawa I, Tokano Y, Takasaki Y, Hashimoto H. Circulating interleukin-16 in systemic lupus erythematosus. Br J Rheumatol 1998;37:1334-7.
73. 73 van der Zee JM, Miltenburg AM, Siegert CE, Daha MR, Breedveld FC. Antiendothelial cell antibodies in systemic lupus erythematosus: Enhanced antibody binding to interleukin-1-stimulated endothelium. Int Arch Allergy Immunol 1994;104:131-6.
74. 74 Sauder DN, Wong D, Laskin C. Epidermal cytokines in murine lupus. J Invest Dermatol 1993;100:42-6S.
75. 75 Nurnberg W, Haas N, Schadendorf D, Czarnetzki BM. Interleukin-6 expression in the skin of patients with lupus erythematosus. Exp Dermatol 1995;4:52-7.
76. 76 Ohtsuka K, Gray JD, Stimmler MM, Toro B, Horwitz DA. Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus. J Immunol 1998;160:2539-45.
77. 77 Alcocer-Varela J, Aleman-Hoey D, Alarcon-Segovia D. Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers. Lupus 1992;1:111-17.
78. 78 Gilad R, Lampl Y, Eshel Y, Barak V, Sarova-Pinhas I. Cerebrospinal fluid soluble interleukin-2 receptor in cerebral lupus. Br J Rheumatol 1997;36:190-3.